Russell J. Cox
CIK 1512984 · Chief Executive Officer · last filed 2026-06-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$23.32M
Companies
3
Total Filings
55
Lifetime Open-Market Net
-$3.23M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Recent Filings · Page 2 of 6
55 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-10 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-11 | GOSS | Grant (A) | — | $0 | EDGAR |
| 2019-06-07 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-02-12 | GOSS | Buy (P) | +7,200 | $115.2K | EDGAR |
| 2019-01-14 | — | Mixed | — | $0 | |
| 2018-06-08 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-04 | — | Grant (A) | — | $0 | |
| 2017-12-13 | JAZZ | Exer (M) | +50,758 | $691.7K | EDGAR |
| 2017-12-05 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-08-09 | JAZZ | Tax (F) | −978 | -$152.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.